VRDN

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Viridian Therapeutics Inc

NASDAQ | VRDN

22.07

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 23, 2025)

$1.79B

Market Cap

-

P/E Ratio

-3.57

EPS

$27.20

52 Week High

$9.90

52 Week Low

HEALTHCARE

Sector

VRDN Chart

Recent Chart
Price Action

VRDN Technicals

Tags:

VRDN Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $302K
Total Revenue $302K
Cost Of Revenue $1.2M
Costof Goods And Services Sold $1.2M
Operating Income -$299M
Selling General And Administrative $61M
Research And Development $238M
Operating Expenses $299M
Investment Income Net -
Net Interest Income $29M
Interest Income $32M
Interest Expense $3M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.2M
Income Before Tax -$270M
Income Tax Expense -$270M
Interest And Debt Expense -
Net Income From Continuing Operations -$270M
Comprehensive Income Net Of Tax -
Ebit -$267M
Ebitda -$266M
Net Income -$270M

Revenue & Profitability

Earnings Performance

VRDN Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $742M
Total Current Assets $738M
Cash And Cash Equivalents At Carrying Value $100M
Cash And Short Term Investments $100M
Inventory -
Current Net Receivables -
Total Non Current Assets $3.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $618M
Other Current Assets $21M
Other Non Current Assets -
Total Liabilities $71M
Total Current Liabilities $48M
Current Accounts Payable $2.1M
Deferred Revenue -
Current Debt -
Short Term Debt $513K
Total Non Current Liabilities $23M
Capital Lease Obligations $513K
Long Term Debt $21M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $21M
Other Current Liabilities $45M
Other Non Current Liabilities $2M
Total Shareholder Equity $672M
Treasury Stock -
Retained Earnings -$996M
Common Stock $810K
Common Stock Shares Outstanding $68M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$232M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.2M
Capital Expenditures $511K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$229M
Cashflow From Financing $458M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$270M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $302K
Total Revenue $302K
Cost Of Revenue $1.2M
Costof Goods And Services Sold $1.2M
Operating Income -$299M
Selling General And Administrative $61M
Research And Development $238M
Operating Expenses $299M
Investment Income Net -
Net Interest Income $29M
Interest Income $32M
Interest Expense $3M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.2M
Income Before Tax -$270M
Income Tax Expense -$270M
Interest And Debt Expense -
Net Income From Continuing Operations -$270M
Comprehensive Income Net Of Tax -
Ebit -$267M
Ebitda -$266M
Net Income -$270M

VRDN News

VRDN Profile

Viridian Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Viridian Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and autoimmune disorders. Based in Boulder, Colorado, the company is focused on leveraging advanced research and development to deliver breakthrough treatments that meet significant unmet medical needs. With a strong pipeline of drug candidates and an unwavering commitment to enhancing patient outcomes, Viridian Therapeutics is poised to play a pivotal role in transforming the therapeutic landscape and addressing the challenges associated with severe diseases.

YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
INTC
+3.35%
$38.15
BURU
-5.27%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
ADAP
-3.44%
$0.07
MSAI
+101.73%
$1.35
AAL
+5.62%
$12.77
BITF
+5.71%
$4.16
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.36%
$2.73
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.29%
$15.67
RF
-0.04%
$24.10
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
BTG
+0.38%
$5.23
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
ONDS
+4.74%
$7.06
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
CIFR
+7.10%
$17.25
PFE
-0.20%
$24.67
TNGX
-13.04%
$7.53
UUUU
-6.50%
$21.26
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
WBD
+3.50%
$21.25
AMZN
+1.44%
$221.09
IREN
+7.77%
$55.86
HPE
+0.43%
$23.19
PBR
+0.93%
$11.84
NIO
+0.73%
$6.89
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.28%
$7.87
BAC
+1.29%
$51.76
RIVN
+1.31%
$13.09
BTE
+5.72%
$2.40
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.65%
$7.79
VALE
-0.52%
$11.46
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
KDLY
+10.41%
$0.79
ELBM
+3.61%
$1.72
NAKA
+10.41%
$0.79
YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
INTC
+3.35%
$38.15
BURU
-5.27%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
ADAP
-3.44%
$0.07
MSAI
+101.73%
$1.35
AAL
+5.62%
$12.77
BITF
+5.71%
$4.16
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.36%
$2.73
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.29%
$15.67
RF
-0.04%
$24.10
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
BTG
+0.38%
$5.23
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
ONDS
+4.74%
$7.06
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
CIFR
+7.10%
$17.25
PFE
-0.20%
$24.67
TNGX
-13.04%
$7.53
UUUU
-6.50%
$21.26
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
WBD
+3.50%
$21.25
AMZN
+1.44%
$221.09
IREN
+7.77%
$55.86
HPE
+0.43%
$23.19
PBR
+0.93%
$11.84
NIO
+0.73%
$6.89
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.28%
$7.87
BAC
+1.29%
$51.76
RIVN
+1.31%
$13.09
BTE
+5.72%
$2.40
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.65%
$7.79
VALE
-0.52%
$11.46
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
KDLY
+10.41%
$0.79
ELBM
+3.61%
$1.72
NAKA
+10.41%
$0.79
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.